

08/958570

Search results

Freeform Search

Database:	<div style="border: 1px solid black; padding: 2px;"> US Pre-Grant Publication Full-Text Database US Patents Full-Text Database US OCR Full-Text Database EPO Abstracts Database JPO Abstracts Database Derwent World Patents Index IBM Technical Disclosure Bulletins </div>
Term:	<div style="border: 1px solid black; padding: 2px;"> L10 and (p53 or p21 or p16 or Rb or WT1 or mitosin or Wilm\$ near tumor) </div>
Display:	<div style="border: 1px solid black; padding: 2px;">100</div> Documents in Display Format: <div style="border: 1px solid black; padding: 2px;">-</div> Starting with Number <div style="border: 1px solid black; padding: 2px;">1</div>
Generate: <input type="radio"/> Hit List <input checked="" type="radio"/> Hit Count <input type="radio"/> Side by Side <input type="radio"/> Image	

Search

Clear

Interrupt

Search History

 DATE: Saturday, April 16, 2005 [Printable Copy](#) [Create Case](#)

<u>Set</u> <u>Name</u> side by side	<u>Query</u>	<u>Hit</u> <u>Count</u>	<u>Set</u> <u>Name</u> result set
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR		
<u>L11</u>	L10 and (p53 or p21 or p16 or Rb or WT1 or mitosin or Wilm\$ near tumor)	29	<u>L11</u>
<u>L10</u>	L9 and (pIX or protein near IX) near5 (delet\$ or lack\$ or absent\$)	31	<u>L10</u>
<u>L9</u>	L8 and tumor near3 suppressor\$	752	<u>L9</u>
<u>L8</u>	replication near5 (deficient\$ or defective) near5 vector\$ near10 adenovir\$	3276	<u>L8</u>
<u>L7</u>	L6 and (thymidine near kinase\$ or cytosine near deaminase)	24	<u>L7</u>
<u>L6</u>	L5 and suicide	24	<u>L6</u>
<u>L5</u>	L3 and E1a and E1b	44	<u>L5</u>
<u>L4</u>	L3 and E1a abd E1b	13976	<u>L4</u>
<u>L3</u>	L2 and (tumor near suppressor\$ or p53 or p21 or WT1 or p16 or mitosin or Rb)	51	<u>L3</u>
<u>L2</u>	L1 and pIX near10 (delet\$ or absent\$ or lack\$)	82	<u>L2</u>
<u>L1</u>	adenovir\$ near5 vector\$	20005	<u>L1</u>

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 82 of 82 returned.**

-
- ☐ 1. [20050031590](#). 18 May 01. 10 Feb 05. Adenoviral vectors having a protein IX deletion. Gregory, Richard, et al. 424/93.2; 435/235.1 435/320.1 435/456 A61K048/00 C12N007/00 C12N015/861.
-
- ☐ 2. [20040266006](#). 27 Jan 04. 30 Dec 04. Adenoviral vectors having a protein IX deletion. Gregory, Richard J., et al. 435/456; 435/235.1 C12N015/861 C12N007/00.
-
- ☐ 3. [20040209247](#). 12 May 04. 21 Oct 04. E1-revertant-free adenoviral composition. Brough, Douglas E., et al. 435/5; C12Q001/70.
-
- ☐ 4. [20040166091](#). 24 Feb 03. 26 Aug 04. Materials and methods for treating disorders of the ear. Brough, Douglas E.. 424/93.2; 435/456 A61K048/00 C12N015/861.
-
- ☐ 5. [20040142470](#). 19 Jul 01. 22 Jul 04. Recombinase-based system for construction of adenovirus vectors. Graham, Frank L., et al. 435/456; 435/235.1 435/320.1 435/325 C12N015/861 C12N007/01 C12N005/06.
-
- ☐ 6. [20040121976](#). 26 Sep 03. 24 Jun 04. Anti-inflammatory vectors. Rooke, Ronald. 514/44; 435/456 A61K048/00 C12N015/86.
-
- ☐ 7. [20040091456](#). 26 Nov 02. 13 May 04. Novel recombinant adenovirus vector with relieved side effects. Nakai, Michio, et al. 424/93.2; 435/456 A61K048/00 C12N015/861.
-
- ☐ 8. [20040087027](#). 23 Jun 03. 06 May 04. Recombinant adenoviral vector and methods of use. Gregory, Richard J., et al. 435/456; 435/235.1 C12N007/00 C12N015/86.
-
- ☐ 9. [20040081637](#). 23 Sep 03. 29 Apr 04. Capsid-modified recombinant adenovirus and methods of use. Curiel, David T.. 424/93.2; 435/235.1 435/456 A61K048/00 C12N007/00 C12N015/861.
-
- ☐ 10. [20040063203](#). 28 Oct 03. 01 Apr 04. Non-adenoviral gene product-based complementing cells for adenoviral vectors. Brough, Douglas E., et al. 435/369; 435/456 C12N005/08 C12N015/861.
-
- ☐ 11. [20040038404](#). 19 May 03. 26 Feb 04. Recombinant adenoviral vector and methods of use. Gregory, Richard J., et al. 435/456; 435/235.1 435/320.1 C12N015/861 C12N007/00.
-
- ☐ 12. [20030228280](#). 31 Jan 03. 11 Dec 03. System for production of helper dependent adenovirus vectors based on use of endonucleases. Graham, Frank L., et al. 424/93.2; 435/235.1 435/325 435/457 A61K048/00 C12N007/00 C12N015/861.
-
- ☐ 13. [20030219410](#). 31 Jan 03. 27 Nov 03. Adenoviral vectors for modulating the cellular activities associated to PODs. Calatrava, Manuel Rosa. 424/93.2; 435/456 A61K048/00 C12N015/861.
-
- ☐ 14. [20030211598](#). 03 Jun 03. 13 Nov 03. Compositions and methods for therapeutic use. Engler, Heidrun, et al. 435/320.1; 424/93.2 435/456 A61K048/00 C12N015/86.
-
- ☐ 15. [20030185801](#). 15 Nov 01. 02 Oct 03. Complementing cell lines. Vogels, Ronald, et al. 424/93.2; 435/235.1 435/325 435/456 A61K048/00 C12N007/00 C12N015/861 C12N005/06

A01N063/00 C12N007/01 C12N005/00 C12N005/02 C12N015/86.

16. [20030171336](#). 04 Jun 02. 11 Sep 03. Complementing cell lines. Vogels, Ronald, et al. 514/100; 435/235.1 435/320.1 435/325 514/44 A61K031/70 A01N043/04 A61K031/665 A01N057/00 C12N007/00 C12N007/01 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74 C12N005/00 C12N005/02.

17. [20030165463](#). 16 Oct 01. 04 Sep 03. Enhanced system for construction of adenovirus vectors. Graham, Frank L., et al. 424/93.2; 424/233.1 435/235.1 435/456 A61K048/00 A61K039/235 C12N007/00 C12N015/861.

18. [20030158112](#). 14 Feb 03. 21 Aug 03. Selective induction of apoptosis to treat ocular disease. Campochiaro, Peter A.. 514/12; 514/44 A61K038/17 A61K048/00.

19. [20030147854](#). 03 Jun 02. 07 Aug 03. Adenovirus vectors for gene therapy. Gregory, Richard J., et al. 424/93.2; 435/235.1 435/320.1 435/456 A61K048/00 C12N007/00 C12N015/861.

20. [20030119192](#). 15 Oct 02. 26 Jun 03. Complementing cell lines. Vogels, Ronald, et al. 435/456; 435/235.1 435/366 C12N007/00 C12N005/08 C12N015/861.

21. [20030108524](#). 18 Oct 02. 12 Jun 03. Vectors for expressing multiple transgenes. Diagana, Melissa, et al. 424/93.2; 435/320.1 435/456 435/6 800/14 A61K048/00 C12Q001/68 A01K067/027 C12N015/861.

22. [20030108521](#). 30 May 02. 12 Jun 03. Adenovirus protein IX, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization. Calatrava, Manuel Rosa. 424/93.2; 424/186.1 435/235.1 435/320.1 435/325 435/456 435/69.3 530/350 536/23.72 A61K048/00 A61K039/12 C07H021/04 C12P021/02 C12N005/06 C07K014/075 C12N007/00 C12N015/861.

23. [20030091534](#). 18 May 01. 15 May 03. Adenoviral vectors having a protein IX deletion. Gregory, Richard, et al. 424/93.2; 435/235.1 435/320.1 435/456 A61K048/00 C12N007/00 C12N015/861.

24. [20030087438](#). 02 Nov 01. 08 May 03. E1-revertant-free adenoviral composition. Brough, Douglas E., et al. 435/456; 435/235.1 435/239 A61K048/00 C12N015/861 C12N007/02 C12N007/00.

25. [20030086904](#). 17 May 02. 08 May 03. Therapeutic regimen for treating cancer. Rasmussen, Henrik S., et al. 424/93.2; 435/235.1 435/456 A61K048/00 C12N007/00 C12N015/861.

26. [20030086903](#). 02 Nov 01. 08 May 03. Therapeutic regimen for treating cancer. Rasmussen, Henrik S., et al. 424/93.1; A01N063/00.

27. [20030054553](#). 23 Jul 01. 20 Mar 03. Adenovector complementing cells. Brough, Douglas E., et al. 435/456; 435/235.1 435/320.1 435/366 C12N015/861 C12N007/00 C12N005/08.

28. [20030053989](#). 14 Sep 01. 20 Mar 03. Method of modulating neovascularization. Kovesdi, Imre. 424/93.2; 435/456 514/44 A61K048/00 C12N015/861.

29. [20030040100](#). 23 Jul 01. 27 Feb 03. Cell for the propagation of adenoviral vectors. Brough, Douglas E., et al. 435/235.1; 435/239 435/325 536/23.72 536/24.1 C12N007/02 C12N005/02 C07H021/04 C12N005/00 C12N007/01 C12N007/00.

-
- ☐ 30. [20030017595](#). 23 Jul 01. 23 Jan 03. Non-adenoviral gene product-based complementing cells for adenoviral vectors. Brough, Douglas E., et al. 435/456; 435/235.1 435/320.1 435/366 C12N015/861 C12N007/01 C12N005/08.
-
- ☐ 31. [20020173039](#). 18 Apr 02. 21 Nov 02. Packaging systems for human recombinant adenovirus to be used in gene therapy. Fallaux, Frits Jacobus, et al. 435/456; 435/235.1 536/23.72 C12N015/861 C07H021/04 C12N007/00.
-
- ☐ 32. [20020168341](#). 16 Oct 01. 14 Nov 02. Enhanced system for construction of adenovirus vectors. Graham, Frank L., et al. 424/93.2; 424/233.1 435/235.1 A61K048/00 A61K039/235 C12N007/00.
-
- ☐ 33. [20020164782](#). 11 May 00. 07 Nov 02. Adenovirus vectors for gene therapy. Gregory, Richard J., et al. 435/320.1; 424/93.2 435/325 A61K048/00 C12N015/74 C12N005/06.
-
- ☐ 34. [20020152486](#). 09 May 01. 17 Oct 02. Vascular specific regulatory elements contained in the desmin 5' flanking region. Paulin, Denise, et al. 800/14; 435/183 435/320.1 435/325 435/69.1 536/23.2 A01K067/027 C07H021/04 C12N009/00 C12P021/02 C12N005/06.
-
- ☐ 35. [20020137212](#). 18 May 01. 26 Sep 02. Adenoviral vectors having a protein IX deletion. Gregory, Richard J., et al. 435/456; 435/235.1 435/320.1 C12N015/861 C12N007/01.
-
- ☐ 36. [20020136708](#). 19 Jun 01. 26 Sep 02. System for production of helper dependent adenovirus vectors based on use of endonucleases. Graham, Frank L., et al. 424/93.21; 435/235.1 435/457 536/23.72 A61K048/00 C07H021/04 C12N007/00 C12N015/861.
-
- ☐ 37. [20020111502](#). 22 Jan 02. 15 Aug 02. Compositions and methods for enhancing delivery of therapeutic agents to cells. Engler, Heidrun, et al. 552/550; 536/53 A61K048/00 A61K031/7008 C07J041/00 C08B037/00 A61K031/56.
-
- ☐ 38. [20020106746](#). 04 Oct 01. 08 Aug 02. Anti-inflammatory vectors. Rooke, Ronald. 435/91.33; 424/199.1 424/204.1 424/233.1 424/93.21 435/235.1 435/320.1 435/456 435/91.41 530/388.7 536/23.72 A61K048/00 C12N007/00 C12N015/861 C07H021/04 C12P019/34 C12N015/64 C12N015/66 A01N063/00 A61K039/12 A61K039/23 A61K039/235 C12N007/01 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74 C07K016/00 C12P021/08 C12N015/86.
-
- ☐ 39. [20020090717](#). 16 Jan 02. 11 Jul 02. Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus. Gao, Guangping, et al. 435/239; 435/235.1 435/367 435/455 435/456 435/464 435/465 435/476 435/70.3 C12P021/04 C12N007/00 C12N007/01 C12N007/02 C12N005/08 C12N015/63 C12N015/85 C12N015/87 C12N015/86 C12N015/74.
-
- ☐ 40. [20020004242](#). 13 Jul 01. 10 Jan 02. Plasmids for construction of eukaryotic viral vectors. McVey, Duncan L., et al. 435/456; 435/320.1 536/23.1 C12N015/86 C07H021/04.
-
- ☐ 41. [20010047081](#). 09 Feb 01. 29 Nov 01. Adenoviral capsid containing chimeric protein IX. Roelvink, Petrus W., et al. 530/350; 435/252.3 C12N001/20 C07K001/00 C07K014/00 C07K017/00.
-
- ☐ 42. [20010039046](#). 26 Jan 01. 08 Nov 01. Viable contaminant particle free adenoviruses, their preparation and use. Yeh, Patrice, et al. 435/320.1; 435/235.1 C12N007/01 C12N015/33.
-

43. 20010016192. 28 Oct 97. 23 Aug 01. RECOMBINANT ADENOVIRAL VECTOR AND METHOD OF USE. GREGORY, RICHARD J., et al. 424/93.2; 424/93.6 435/320.1 435/455 435/456 435/69.1 A61K048/00 C12N015/861.
-
44. 20010006946. 08 Jul 98. 05 Jul 01. COMPOSITIONS AND METHODS FOR ENHANCING DELIVERY OF THERAPEUTIC AGENTS TO CELLS. ENGLER, HEIDRUN, et al. 514/44; 424/93.1 A61K048/00.
-
45. 20010006629. 24 Nov 99. 05 Jul 01. RECOMBINANT ADENOVIRAL VECTOR AND METHODS OF USE. GREGORY, RICHARD J., et al. 424/93.1; 424/93.2 424/93.6 435/320.1 514/44 A61K048/00 C12N015/861.
-
46. 6869794. 04 Jun 02; 22 Mar 05. Complementing cell lines. Vogels; Ronald, et al. 435/325; 435/235.1 435/41 435/69.1. C12N00502 C12N00700 C12P00100 C12P02106.
-
47. 6855534. 16 Oct 01; 15 Feb 05. Enhanced system for construction of adenovirus vectors. Graham; Frank L., et al. 435/235.1; 435/320.1. C12N00700 C12N001861.
-
48. 6830920. 08 Mar 00; 14 Dec 04. Rapid generation of recombinant adenoviral vectors. Davidson; Beverly L., et al. 435/235.1; 435/320.1 435/325 435/462 435/463 435/466 435/475 435/476 435/477 435/91.42 536/23.72. C12N015/64 C12N007/00 C12N005/00 C12N015/00 C12N015/86 C12N015/861 C07H021/04.
-
49. 6814962. 16 Nov 00; 09 Nov 04. Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same. Benoit; Patrick, et al. 424/93.2; 435/320.1 435/455 435/91.4 514/44. A61K048/00.
-
50. 6764674. 27 Dec 99; 20 Jul 04. Adenovirus E1B shuttle vectors. Hermiston; Terry, et al. 424/93.2; 435/235.1 435/320.1 435/325 435/358 435/365 435/367 435/455 435/456 435/471. A01N063/00 A61K048/00.
-
51. 6756226. 16 Oct 01; 29 Jun 04. Enhanced system for construction of adenovirus vectors. Graham; Frank L., et al. 435/320.1; 435/456 435/91.4 514/44. C12N015/64 C12N001/00 C12N015/00 C12N015/09 C12N015/63.
-
52. 6753321. 14 Sep 01; 22 Jun 04. Method of modulating neovascularization. Kovesdi; Imre. 514/44; 424/93.2 435/320.1 435/455 435/456. A61K048/00.
-
53. 6740525. 09 Feb 01; 25 May 04. Adenoviral capsid containing chimeric protein IX. Roelvink; Petrus W., et al. 435/456; 435/235.1 435/236 435/320.1 435/325 435/366 435/455 435/457 435/5 435/6 435/7.1 530/324 530/325 530/326 530/350 536/23.1 536/23.4 536/23.72. C12N015/34 C12N015/63 C12N015/861 C07H021/04 C07K014/075.
-
54. 6692956. 04 Oct 01; 17 Feb 04. Recombinant adenoviral vectors. Rooke; Ronald. 435/320.1; 424/233.1. C12N015/63 C12N015/00.
-
55. 6682929. 23 Jul 01; 27 Jan 04. Adenovector complementing cells. Brough; Douglas E., et al. 435/371; 435/320.1 435/325 435/366. C12N005/10 C12N015/861.
-

- ☐ 56. [6677156](#). 23 Jul 01; 13 Jan 04. Non-adenoviral gene product-based complementing cells for adenoviral vectors. Brough; Douglas E., et al. 435/456; 435/320.1 435/325 435/366 435/367 435/368 435/369 435/370 435/371 435/372 435/372.1 435/372.2 435/373 435/455 435/457. C12N005/10 C12N015/63 C12N015/861.
-
- ☐ 57. [6596269](#). 24 Aug 01; 22 Jul 03. Methods of treating chronic pain. Iadarola; Michael J., et al. 424/93.2; 424/199.1 435/235.1 435/320.1. A61K048/00 C12N015/86 C12N015/861 C12N015/864.
-
- ☐ 58. [6566128](#). 15 Nov 99; 20 May 03. Adenovirus vectors generated from helper viruses and helper-dependent vectors. Graham; Frank L., et al. 435/325; 424/93.1 424/93.2 424/93.21 435/320.1. A61K048/00 C12N015/74 C12N005/00.
-
- ☐ 59. [6482617](#). 26 Jan 01; 19 Nov 02. Viable contaminant particle free adenoviruses, their preparation and use. Yeh; Patrice, et al. 435/91.4; 424/93.2 435/320.1 435/455 435/456 435/91.1 435/91.41 435/91.42. C12N015/64 C12N015/861 A61K048/00.
-
- ☐ 60. [6475757](#). 13 Jul 01; 05 Nov 02. Plasmids for construction of eukaryotic viral vectors. McVey; Duncan L., et al. 435/91.41; 435/320.1 435/455 435/456 435/463 435/5 435/6 435/91.1 435/91.4 435/91.52. C12N015/63 C12N015/64 C12N015/861 C12N015/864 C12N015/869.
-
- ☐ 61. [6475480](#). 06 Jul 99; 05 Nov 02. Use of adenoviral E4 reading frames to improve expression of a gene of interest. Mehtali; Majid, et al. 424/93.2; 435/235.1 435/320.1 435/440 435/455 435/456 514/44. A01N063/00 A01N043/04 C12N015/00 C12N007/00 C12N015/63.
-
- ☐ 62. [6410298](#). 11 Sep 00; 25 Jun 02. Adenovirus vectors and method for reducing homologous recombination phenomena. Crouzet; Joel, et al. 435/235.1; 435/325 435/5 435/6 435/69.1 536/23.1. C12N007/00 C12Q001/70 C12Q001/68 C12P021/06 C07H021/02.
-
- ☐ 63. [6392069](#). 08 Jul 98; 21 May 02. Compositions for enhancing delivery of nucleic acids to cells. Engler; Heidrun, et al. 552/509; 536/5. C07J053/00.
-
- ☐ 64. [6379943](#). 05 Mar 99; 30 Apr 02. High-efficiency Cre/loxP based system for construction of adenovirus vectors. Graham; Frank L., et al. 435/235.1; 435/320.1 435/325 435/366 435/369. C12N005/10 C12N007/01 C12N015/861.
-
- ☐ 65. [6365394](#). 11 Sep 00; 02 Apr 02. Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus. Gao; Guangping, et al. 435/239; 435/235.1 435/367 435/455 435/456 435/464 435/465 435/476 435/70.3. C12N007/00 C12N015/64 C12N007/02 C12P001/00.
-
- ☐ 66. [6329200](#). 25 Feb 00; 11 Dec 01. Plasmids for construction of eukaryotic viral vectors. McVey; Duncan L., et al. 435/320.1; 435/91.4 435/91.41 435/91.42 536/23.1 536/24.1. C12N015/63 C12N015/64 C07H021/04.
-
- ☐ 67. [6312946](#). 22 Apr 97; 06 Nov 01. Viable contaminant particle free adenoviruses, their preparation and use. Yeh; Patrice, et al. 435/320.1; 424/93.2 424/93.21 435/455 435/456 514/44. C12N015/861 A61K048/00.
-
- ☐ 68. [6210939](#). 25 Oct 94; 03 Apr 01. Recombinant adenoviral vector and methods of use. Gregory; Richard J., et al. 435/456; 435/252.3 435/320.1 435/363 435/366 435/370 435/371. C12N005/10

C12N015/10 C12N015/63 C12N015/86.

-
- ☐ 69. [6165779](#). 07 Jan 97; 26 Dec 00. Compositions and methods for therapeutic use. Engler; Heidrun, et al. 435/320.1; 424/199.1 435/235.1 514/44. C12N015/63 C12N007/00 A61K038/00 A61K048/00.
-
- ☐ 70. [6093567](#). 10 Feb 99; 25 Jul 00. Gene therapy for cystic fibrosis. Gregory; Richard J., et al. 435/320.1; 424/93.2. A61K048/00.
-
- ☐ 71. [6080569](#). 25 Sep 96; 27 Jun 00. Adenovirus vectors generated from helper viruses and helper-dependent vectors. Graham; Frank L., et al. 435/235.1; 435/320.1 435/440 435/455 435/457. C12N007/00 C12N015/63 C12N015/09 C12N015/83.
-
- ☐ 72. [6033908](#). 15 Jul 97; 07 Mar 00. Packaging systems for human recombinant adenovirus to be used in gene therapy. Bout; Abraham, et al. 435/325; 424/93.21 435/320.1 435/455 435/69.1 514/44 536/23.1. C12N015/00.
-
- ☐ 73. [5994128](#). 25 Mar 97; 30 Nov 99. Packaging systems for human recombinant adenovirus to be used in gene therapy. Fallaux; Frits Jacobus, et al. 435/325; 424/93.21 435/320.1 435/455 435/69.1 536/23.1. C12N015/00.
-
- ☐ 74. [5981275](#). 14 Apr 97; 09 Nov 99. Transgene expression system for increased persistence. Armentano; Donna, et al. 435/320.1; C12N015/00.
-
- ☐ 75. [5962429](#). 22 Nov 96; 05 Oct 99. Complexes of adenovirus with cationic molecules. Welsh; Michael J., et al. 514/44; 424/93.2 424/93.6 435/455 435/456. A61K048/00.
-
- ☐ 76. [5932210](#). 28 Oct 97; 03 Aug 99. Recombinant adenoviral vector and methods of use. Gregory; Richard J., et al. 424/93.2; 424/93.6 435/320.1. A61K048/00 C12N015/86.
-
- ☐ 77. [5882877](#). 16 Jul 97; 16 Mar 99. Adenoviral vectors for gene therapy containing deletions in the adenoviral genome. Gregory; Richard J., et al. 435/320.1; 435/456 435/457. C12N015/00 C12N015/86.
-
- ☐ 78. [5670488](#). 13 Oct 93; 23 Sep 97. Adenovirus vector for gene therapy. Gregory; Richard J., et al. 514/44; 424/93.2 435/320.1. A61K048/00 C12N015/00.
-
- ☐ 79. [WO003064666A1](#). 31 Jan 03. 07 Aug 03. ADENOVIRAL VECTORS FOR MODULATING THE CELLULAR ACTIVITIES ASSOCIATED WITH PODS. ROSA-CALATRAVA, MANUEL. C12N015/861; C07K014/075 A61K048/00.
-
- ☐ 80. [US 6764674B](#). New recombinant adenoviral vector comprises a deletion in the Elb region, useful for gene therapy, e.g. treating or preventing diseases including neoplastic conditions. HERMISTON, T, et al. A01N063/00 A61K048/00.
-
- ☐ 81. [US20020136708A](#). New helper-dependent adenovirus vector for producing helper adenovirus, expressing foreign DNA in mammalian cells, vaccines and for gene therapy. ANGLANA, M, et al. A61K048/00 C07H021/04 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N007/00 C12N015/09 C12N015/10 C12N015/85 C12N015/86 C12N015/861.
-
- ☐ 82. [US 6080569A](#). Improved helper-dependent vector system comprising loxP sites - used for production of high capacity adenoviral cloning vector(s). CHEN, L, et al. A61K048/00 C12N005/00

C12N005/10 C12N007/00 C12N015/09 C12N015/63 C12N015/74 C12N015/83 C12N015/86
C12Q001/66 C12Q001/70.

[Generate Collection](#)[Print](#)

Terms	Documents
L1 and pIX near10 (delet\$ or absent\$ or lack\$)	82

[Prev Page](#) [Next Page](#) [Go to Doc#](#)



Day : Saturday
Date: 4/16/2005

Time: 14:34:41

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name

First Name

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

**PALM INTRANET**Day : Saturday
Date: 4/16/2005

Time: 14:34:41

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Day : Saturday
Date: 4/16/2005

Time: 14:34:41

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name

First Name

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)